Search
                    Connecticut Paid Clinical Trials
A listing of 1248  clinical trials  in Connecticut  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            1153 - 1164 of 1248
        
                Connecticut is currently home to 1248 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
            
                                                Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    Featured Trial
                
                Ischemic heart disease (IHD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Ischemic heart disease (IHD)
    
    
                            Conditions: 
                                    
        
            
                        Ischemic heart disease (IHD)
                    
                                    
                
                                    Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping
                                
            
            
        Recruiting
                            
            
                In this study, a new method will be used to evaluate response to 2 approved biologic therapies, and assess how well each patient responds to each asthma treatment. This study will measure the response to these treatments using genomic and biologic measurements obtained from participants biosamples.
By evaluating response to 2 different biologic therapies, this study has the potential to provide an in-depth understanding of the mechanisms underlying severe asthma that will inform and change trea...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 75 years
            Trial Updated:
                08/16/2024
            
            Locations: Yale University, New Haven, Connecticut         
        
        
            Conditions: Moderate to Severe Asthma
        
            
        
    
                
                                    A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma
                                
            
            
        Recruiting
                            
            
                Primary Objective: To assess the activity of Afatinib in patients with persistent or recurrent uterine serous carcinoma overexpressing HER2/neu with the frequency of patients who survive progression-free for at least 6 months after initiating therapy. Secondary Objectives: To assess objective response rate and durable disease control rate. To assess overall survival. To assess the safety profile of Afatinib in uterine serous carcinoma patients.             
        
        
    Gender:
                FEMALE
            Ages:
                Between 18 years and 100 years
            Trial Updated:
                08/16/2024
            
            Locations: Yale New Haven Hospital, New Haven, Connecticut         
        
        
            Conditions: HER2/Neu+ Uterine Serous Carcinoma
        
            
        
    
                
                                    Evaluation of a Claims-based Algorithm for the Identification of Transthyretin-mediated Amyloidosis (ATTR) Amyloidosis in Medical Records
                                
            
            
        Recruiting
                            
            
                The primary objective of this study is to evaluate the diagnostic performance of an algorithm in identifying patients with ATTR amyloidosis.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/14/2024
            
            Locations: Yale New Haven Hospital, New Haven, Connecticut         
        
        
            Conditions: Transthyretin Amyloidosis
        
            
        
    
                
                                    Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
                                
            
            
        Recruiting
                            
            
                This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.             
        
        
    Gender:
                MALE
            Ages:
                18 years and above
            Trial Updated:
                08/14/2024
            
            Locations: Smilow Cancer Hospital Care Center - Guilford, Guilford, Connecticut         
        
        
            Conditions: Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
        
            
        
    
                
                                    Imaging SV2A in Mood Disorders
                                
            
            
        Recruiting
                            
            
                This study is designed to examine SV2A density in MDD and PTSD as a correlate of synaptic density, and to determine whether ketamine administration will reverse the synaptic loss in vivo in human subjects. To our knowledge, this is the first human study to examine SV2A in vivo in MDD and PTSD and to use the first known drug (ketamine) that rapidly reverses synaptic loss to determine whether ketamine administration could restore some of the structural changes associated with depression and PTSD....  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 70 years
            Trial Updated:
                08/08/2024
            
            Locations: PET Center, New Haven, Connecticut         
        
        
            Conditions: Major Depressive Disorder, Post-Traumatic Stress Disorder
        
            
        
    
                
                                    Normative Database and Test-Retest Reliability for BrainCheck Assessments
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to collect normative test values and demographic information for normative and referential data for a rapid, portable, computerized neurocognitive testing device from healthy adults 50 and older.             
        
        
    Gender:
                ALL
            Ages:
                50 years and above
            Trial Updated:
                08/07/2024
            
            Locations: Maplewood Senior Living, Multiple Locations, Connecticut         
        
        
            Conditions: Cognitive Change, Cognitive Decline, Cognitive Deterioration, Neurocognitive Deficit
        
            
        
    
                
                                    ABTECT - Maintenance
                                
            
            
        Recruiting
                            
            
                This is a multicenter, randomized, placebo-controlled study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies \[corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)\] and/or advanced therapies \[biologics (TNF inhi...  Read More             
        
        
    Gender:
                ALL
            Ages:
                16 years and above
            Trial Updated:
                08/06/2024
            
            Locations: Danbury Hospital, Danbury, Connecticut         
        
        
            Conditions: Ulcerative Colitis
        
            
        
    
                
                                    Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to compare any good or bad effects of using pembrolizumab (an experimental drug) and radiation therapy (RT), compared to using cisplatin chemotherapy and radiation therapy (RT) in the treatment of patients with head and neck squamous cell carcinoma (HNSCC).             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/02/2024
            
            Locations: Yale Cancer Center, New Haven, Connecticut         
        
        
            Conditions: Head and Neck Squamous Cell Carcinoma, Cancer, Cancer of Head and Neck, Cancer, Advanced, Cancer, Metastatic, Tumor, Tumor Recurrence, Tumor Neck, Tumor Metastasis, Oral Cancer, Oropharyngeal Cancer, Oropharynx Cancer, Oropharynx Cancer, Stage III, Oropharynx Cancer, Recurrent, Oropharynx Cancer, Metastatic
        
            
        
    
                
                                    Effect of TXA Oral Sol 5% in Patients Treated With DOACs or VKA and Undergoing a Single or Multiple Tooth Extraction
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to assess the effect of Tranexamic Acid Oral Solution 5% in patients treated with direct oral anticoagulants or vitamin K antagonists and undergoing a single or multiple tooth extraction.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 99 years
            Trial Updated:
                07/31/2024
            
            Locations: Stamford Therapeutics Consortium, Stamford, Connecticut         
        
        
            Conditions: Bleeding From Teeth, Bleeding Prophylaxis
        
            
        
    
                
                                    A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease
                                
            
            
        Recruiting
                            
            
                A Phase 1b Multiple Ascending Dose Study of the Safety and Tolerability of BMS-984923 in Healthy Older Adults and Patients with Alzheimer's Disease             
        
        
    Gender:
                ALL
            Ages:
                Between 50 years and 80 years
            Trial Updated:
                07/29/2024
            
            Locations: Yale University, New Haven, Connecticut         
        
        
            Conditions: Alzheimer's Disease
        
            
        
    
                
                                    Expanding Medication-Assisted Therapies in Central Asia
                                
            
            
        Recruiting
                            
            
                Central Asia (CA) represents the most rapidly growing HIV epidemic region worldwide, concentrated in people who inject drugs (PWID) and their sexual partners, and scaling up opioid agonist therapies (OAT) in this region is the most cost-effective strategy to prevent new HIV infections, and more effective when combined with antiretroviral therapy (ART). The investigators propose to use the Network for the Improvement of Addiction Treatment (NIATx) implementation strategy to scale-up OAT in three...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                07/24/2024
            
            Locations: Yale University, New Haven, Connecticut         
        
        
            Conditions: Opioid Use Disorder
        
            
        
    
                
                                    Vitamin D in OUD: Exploration of Alterations on the Dopamine D2/D3 Receptor System
                                
            
            
        Recruiting
                            
            
                The research team is investigating Opioid Use Disorder (OUD), a disorder characterized by dysregulated dopaminergic tone, to evaluate the mechanisms of adjunctive treatment with calcitriol. The investigators will recruit 12 subjects with OUD and 12 healthy subjects to participate in a double-blind, randomized study design where subjects will complete up to 2 Positron Emission Tomography (PET) scans using \[11C\]-PHNO. The investigators will compare subjects in differences between their own study...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 50 years
            Trial Updated:
                07/22/2024
            
            Locations: Yale School of Medicine, New Haven, Connecticut         
        
        
            Conditions: Opioid Use Disorder
        
            
        
    